| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/CAD.0000000000001004 |
| P698 | PubMed publication ID | 33038083 |
| P2093 | author name string | Lei Zhang | |
| Hui Zhang | |||
| Xiaofei Wang | |||
| Xinxin Zhang | |||
| Xuanji Xue | |||
| Zengjun Guo | |||
| Xiaochen Niu | |||
| Guanqun Zhan | |||
| P2860 | cites work | Global cancer statistics | Q22241238 |
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| Phylogeny of the SOX family of developmental transcription factors based on sequence and structural indicators | Q28143448 | ||
| 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal | Q28384242 | ||
| Identification of a human glioma antigen, SOX6, recognized by patients' sera | Q31033978 | ||
| Induction of protective and therapeutic antitumor immunity by a DNA vaccine with a glioma antigen, SOX6. | Q33316774 | ||
| DNA methylation and breast carcinogenesis. | Q34770599 | ||
| Promoter methylation and expression changes of BRCA1 in cancerous tissues of patients with sporadic breast cancer | Q35167715 | ||
| Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification | Q35633666 | ||
| DNA methylation outliers in normal breast tissue identify field defects that are enriched in cancer | Q36540420 | ||
| Sox5 induces epithelial to mesenchymal transition by transactivation of Twist1. | Q39017400 | ||
| Characterization of tumor-suppressive function of SOX6 in human esophageal squamous cell carcinoma. | Q39630589 | ||
| Association of the hypermethylation status of PTEN tumor suppressor gene with the risk of breast cancer among Kurdish population from Western Iran | Q41012393 | ||
| Multistep carcinogenesis of breast cancer and tumour heterogeneity | Q41540149 | ||
| Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. | Q43247519 | ||
| MiR-96 targets SOX6 and promotes proliferation, migration and invasion of hepatocellular carcinoma. | Q47822642 | ||
| Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic Stat3. | Q47866372 | ||
| A study on promoter methylation of PTEN in sporadic breast cancer patients from North India | Q48666856 | ||
| miR-671 promotes prostate cancer cell proliferation by targeting tumor suppressor SOX6. | Q49885496 | ||
| Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases | Q53666037 | ||
| Mismatch repair and drug responses in cancer | Q53998965 | ||
| Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer | Q57390853 | ||
| SOX6 blocks the proliferation of BCR-ABL1 and JAK2V617F leukemic cells | Q64069797 | ||
| BRCA Mutational Status is a Promising Predictive Biomarker for Platinum-based Chemotherapy in Triple-Negative Breast Cancer | Q89513595 | ||
| Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives | Q90226704 | ||
| Breast cancer statistics, 2019 | Q90435626 | ||
| SOX6 suppresses the development of lung adenocarcinoma by regulating expression of p53, p21CIPI , cyclin D1 and β-catenin | Q91293507 | ||
| P577 | publication date | 2020-10-07 | |
| P1433 | published in | Anti-Cancer Drugs | Q4774128 |
| P1476 | title | SRY-related high-mobility-group box 6 suppresses cell proliferation and is downregulated in breast cancer |
Search more.